Actuate Therapeutics' Unattributed Round

Actuate Therapeutics raised a round of funding on March 20, 2017.

Actuate Therapeutics focuses on the development of compounds for combination use in high impact carcinomas including glioblastoma, ovarian, breast, and pancreatic cancers. The company has completed st…

Articles about Actuate Therapeutics' Unattributed Round: